Delstrigo 100 mg/300 mg/245 mg film-coated tablets

DRUG4 trials

Sponsors

Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La C, Centre Hospitalier Universitaire De Caen Normandie, Inserm, Stichting Radboud universitair medisch centrum

Conditions

HIV-1 infectionHIV-infectedHuman Immunodeficiency VirusPatients living with HIV-1 who are virologically controlled and carry an M184V/I mutation in a previous genotype

Phase 2

Efficacy of the Doravirine/Tenofovir Disoproxil Fumarate/Lamivudine combination in people living with HIV with a history of M184V/I mutation and virologically controlled: a phase II, open-label, non-comparative pilot study.

RecruitingCTIS2023-505845-17-00

Centre Hospitalier Universitaire De Caen NormandiePatients living with HIV-1 who are virologically controlled and carry an M184V/I mutation in a previous genotype

Start: 2024-02-08Target: 32Updated: 2025-11-05

Phase 3

ANRS0392s ELDORADO : Phase III, open-label, randomized, multicenter trial EvaLuating the non-inferiority of DORAvirine versus DOlutegravir based antiretroviral regimens in treatment-naïve people living with HIV-1 infection

RecruitingCTIS2023-508626-10-00

InsermHIV-1 infection

Start: 2025-01-08Target: 60Updated: 2025-10-15

Phase 4

Impact of Doravirine in Liver Steatosis and Fibrosis in PLWH. A pilot, proof of concept study (DORALI Study)

RecruitingCTIS2023-504952-87-00

Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La CHuman Immunodeficiency Virus

Start: 2025-01-13Target: 50Updated: 2024-09-18

Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)

CompletedCTIS2024-515487-31-00

Stichting Radboud universitair medisch centrumHIV-infected

End: 2025-12-12Target: 163Updated: 2024-10-22